CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

21 Mar 2023 15:10:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

15 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

22 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

16 Feb 2023 09:30:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

16 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two February 2023 Scientific Conferences

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Announces Chief Medical Officer Transition

23 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

22 Nov 2022 07:00:04 By Nasdaq GlobeNewswire

Cue Biopharma Reports Third Quarter 2022 Financial Results

14 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

14 Nov 2022 07:20:14 By Nasdaq GlobeNewswire

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

09 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

04 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two September 2022 Scientific Conferences

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

22 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2022 Financial Results

04 Aug 2022 15:30:00 By Nasdaq GlobeNewswire